Formulation, characterization and permeability study of nano particles of lipo-endomorphin-1 for oral delivery

References

• Allémann E, Leroux JC, Gurny R. (1998). Polymeric nano-and microparticles for the oral delivery of peptides and peptidomimetics. Adv Drug Deliv Rev 34:171–89
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceut Res 12:413–20
   PubMed Web of Science ®Google Scholar
• Avdeef A. (2007). Solubility of sparingly-soluble ionizable drugs. Adv Drug Deliv Rev 59:568–90
   PubMed Web of Science ®Google Scholar
• Barea MEJ. (2012). An investigation into liposomal formulations for targeted drug delivery to the colon. UK: University of Birmingham
   Google Scholar
• Barea M, Jenkins M, Gaber M, Bridson R. (2010). Evaluation of liposomes coated with a pH responsive polymer. Int J Pharmaceut 402:89–94
   PubMed Web of Science ®Google Scholar
• Bouchemal K, Briançon S, Perrier E, Fessi H. (2004). Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation. Int J Pharmaceut 280:241–51
   PubMed Web of Science ®Google Scholar
• Brockman H. (2000). Kinetic behavior of the pancreatic lipase-colipase-lipid system. Biochimie 82:987–95
   PubMed Web of Science ®Google Scholar
• Cetin M, Aktas MS, Vural I, Ozturk M. (2012). Salmon calcitonin-loaded Eudragit® and Eudragit®-PLGA nanoparticles: in vitro and in vivo evaluation. J Microencapsul 29:156–66
   PubMed Web of Science ®Google Scholar
• Czapla MA, Gozal D, Alea OA, et al. (2000). Differential cardiorespiratory effects of endomorphin 1, endomorphin 2, DAMGO, and morphine. Am J Respirat Crit Care Med 162:994–9
   PubMed Web of Science ®Google Scholar
• Delie F, Blanco-prieto MJ. (2005). Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules 10:65–80
   PubMed Web of Science ®Google Scholar
• des rieux A, Fievez V, Garinot M, et al. (2006). Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Rel 116:1–27
   PubMed Web of Science ®Google Scholar
• Dogru S, Calis S, Öner F. (2001). Oral multiple w/o/w emulsion formulation of a peptide salmon calcitonin: in vitro--in vivo evaluation. J Clin Phar Therapeut 25:435–43
   Web of Science ®Google Scholar
• El-kamel AH, Sokar MS, Al gamal SS, Naggar VF. (2001). Preparation and evaluation of ketoprofen floating oral delivery system. Int J Pharmaceut 220:13–21
   PubMed Web of Science ®Google Scholar
• Eratalay A, Öner F, Özcengiz E, Alpar R. (2004). Adjuvant effects of niosome and water/oil/water multiple emulsion carrier systems for recombinant hepatitis b surface antigen. Hacettepe University. J Faculty Pharm 24:81–94
   Google Scholar
• Gupta H, Sharma A. (2009). Recent trends in protein and peptide drug delivery systems. Asian J Pharmaceut 3:69--75
   Google Scholar
• Hamman JH, Enslin GM, Kotze AF. (2005). Oral delivery of peptide drugs: barriers and developments. BioDrugs 19:165–77
   PubMed Web of Science ®Google Scholar
• Hu F, Yuan H, Zhang H, Fang M. (2002). Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int J Pharmaceut 239:121–8
   PubMed Web of Science ®Google Scholar
• Iwanaga K, Ono S, Narioka K, et al. (1999). Application of surface-coated liposomes for oral delivery of peptide: effects of coating the liposome's surface on the GI transit of insulin. J Pharmaceut Sci 88:248–52
   PubMed Web of Science ®Google Scholar
• Jacobs C, Kayser O, Müller R. (2000). Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharmaceut 196:161–4
   PubMed Web of Science ®Google Scholar
• Jain D, Panda AK, Majumdar DK. (2005). Eudragit S100 entrapped insulin microspheres for oral delivery. AAPS Pharmscitech 6:100–7
   PubMed Web of Science ®Google Scholar
• Karn PR, Vanić Z, Pepić I, Škalko-Basnet N. (2011). Mucoadhesive liposomal delivery systems: the choice of coating material. Drug Dev Ind Pharm 37:482–8
   PubMed Web of Science ®Google Scholar
• Keresztes A, Birkás E, Páhi A, et al. (2011). Pharmacology of a new tritiated endomorphin-2 analog containing the proline mimetic cis-2-aminocyclohexanecarboxylic acid. Peptides 32:722–8
   PubMed Web of Science ®Google Scholar
• Kim B, Peppas NA. (2003). In vitro release behavior and stability of insulin in complexation hydrogels as oral drug delivery carriers. Int J Pharmaceut 266:29–37
   PubMed Web of Science ®Google Scholar
• Koda Y, Del borgo M, Wessling ST, et al. (2008). Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. Bioorg Med Chem 16:6286–96
   PubMed Web of Science ®Google Scholar
• Kolter K, Subkowski T, Raditsch M, Schehlmann V. (2003). Use of (meth) acrylic acid copolymers to increase the permeability of mucous membranes. Google Patents
   Google Scholar
• Lopedota A, Trapani A, Cutrignelli A, et al. (2009). The use of Eudragit® RS 100/cyclodextrin nanoparticles for the transmucosal administration of glutathione. Eur J Pharmaceut Biopharmaceut 7:509–20
   Google Scholar
• Mahato RI, Narang AS, Thoma L, Miller DD. (2003). Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 20:153–214
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mäder K. (2001). Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 47:165--96
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Ray S, Thakur RS. (2009). Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Ind J Pharmaceut Sci 71:349--58
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharmaceut Biopharmaceut 50:161–77
   PubMed Web of Science ®Google Scholar
• Müllertz A. (2007). Biorelevant dissolution media. Solvent systems and their selection in pharmaceutics and biopharmaceutics. New York: Springer
   Google Scholar
• Mustata G, Dinh SM. (2006). Approaches to oral drug delivery for challenging molecules. Crit Rev Therapeut Drug Carrier Syst 23:111–35
   PubMed Web of Science ®Google Scholar
• Nguyen DA, Fogler HS. (2005). Facilitated diffusion in the dissolution of carboxylic polymers. AIChE J 51:415–25
   Web of Science ®Google Scholar
• Olbrich C, Kayser O, Müller RH. (2002). Enzymatic degradation of Dynasan 114 SLN – effect of surfactants and particle size. J Nanoparticle Res 4:121–9
   Web of Science ®Google Scholar
• Patravale V, Date AA, Kulkarni R. (2004). Nanosuspensions: a promising drug delivery strategy. J Pharma Pharmacol 56:827–40
   Web of Science ®Google Scholar
• Paul W, Sharma CP. (2008). Tricalcium phosphate delayed release formulation for oral delivery of insulin: a proof-of-concept study. J Pharmaceut Sci 97:875–82
   PubMed Web of Science ®Google Scholar
• Perlikowska R, Fichna J, Wyrebska A, et al. (2009). Design, synthesis and pharmacological characterization of endomorphin analogues with non-cyclic amino acid residues in position 2. Basic Clin Pharmacol Toxicol 106:106–13
   PubMed Web of Science ®Google Scholar
• Pharmacopeia U. (2005). Chapter 711 Dissolution. Physical Tests 2:2412–14
   Google Scholar
• Przewlocki R, Przewlocka B. (2001). Opioids in chronic pain. Eur J Pharmacol 429:79–91
   PubMed Web of Science ®Google Scholar
• Rawat M, Saraf S. (2007). Influence of selected formulation variables on the preparation of enzyme-entrapped eudragit S100 microspheres. AAPS Pharmscitech 8:289–97
   Web of Science ®Google Scholar
• Sahlin A, Lodén M, Åkerström U, Neimert K. (2008). Topical formulations. EP Patent 1,941,860, A1:1--22
   Google Scholar
• Sakurada S, Watanabe H, Hayashi T, et al. (2002). Endomorphin analogues containing D-Pro(2) discriminate different mu-opioid receptor mediated antinociception in mice. Br J Pharmacol 137:1143–6
   PubMed Web of Science ®Google Scholar
• Santos-magalhães N, Pontes A, Pereira V, Caetano M. (2000). Colloidal carriers for benzathine penicillin G: nanoemulsions and nanocapsules. Int J Pharmaceut 208:71–80
   PubMed Web of Science ®Google Scholar
• Schubert MA, Müller-Goymann CC. (2003). Solvent injection as a new approach for manufacturing lipid nanoparticles – evaluation of the method and process parameters. Eur J Pharmaceut Biopharmaceut 55:125–31
   PubMed Web of Science ®Google Scholar
• Shaji J, Patole V. (2008). Protein and peptide drug delivery: oral approaches. Ind J Pharmaceut Sci 70:269--77
   PubMed Web of Science ®Google Scholar
• Sharma M, Sharma V, Panda AK, Majumdar DK. (2011). Development of enteric submicron particle formulation of papain for oral delivery. Int J Nanomed 6:2097--111
   PubMed Web of Science ®Google Scholar
• Sood A, Panchagnula R. (2001). Peroral route: an opportunity for protein and peptide drug delivery. Chem Rev-Columbus 101:3275–304
   PubMed Web of Science ®Google Scholar
• Staniland P, Chahal S, Tooley I, Sayer R. (2011). Protection against photoageing. Focus Sun Care 3:20--3
   Google Scholar
• Takeuchi H, Matsui Y, Yamamoto H, Kawashima Y. (2003). Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J Control Rel 86:235–42
   PubMed Web of Science ®Google Scholar
• Thompson C, Ibie C. (2011). The oral delivery of proteins using interpolymer polyelectrolyte complexes. Therapeut Deliv 2:1611–31
   PubMedGoogle Scholar
• Tömböly C, Péter A, Tóth G. (2002). In vitro quantitative study of the degradation of endomorphins. Peptides 23:1573–80
   PubMed Web of Science ®Google Scholar
• Toth I. (1994). A novel chemical approach to drug delivery: lipidic amino acid conjugates. J Drug Target 2:217–39
   PubMed Web of Science ®Google Scholar
• Varamini P, Mansfeld FM, Blanchfield JT, et al. (2012a). Lipo-endomorphin-1 derivatives with systemic activity against neuropathic pain without producing constipation. PLoS ONE 7:e41909
   Google Scholar
• Varamini P, Mansfeld FM, Blanchfield JT, et al. (2012b). Synthesis and biological evaluation of an orally active glycosylated endomorphin-1. J Med Chem 55:5859–67
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Eskandari S, Tabakhian M. (2010). Production and optimization of valproic acid nanostructured lipid carriers by the Taguchi design. Pharm Dev Technol 15:89–96
   PubMed Web of Science ®Google Scholar
• Wolfe D, Hao S, Hu J, et al. (2007). Engineering an endomorphin-2 gene for use in neuropathic pain therapy. Pain 133:29–38
   PubMed Web of Science ®Google Scholar
• Yoo J-W, Giri N, Lee CH. (2011). pH-sensitive Eudragit nanoparticles for mucosal drug delivery. Int J Pharmaceut 403:262–7
   PubMed Web of Science ®Google Scholar
• Yu LX, Amidon GL, Polli JE, et al. (2002). Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharmaceut Res 19:921–5
   PubMed Web of Science ®Google Scholar
• Zhuang CY, Li N, Wang M, et al. (2010). Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharmaceut 394:179–85
   PubMed Web of Science ®Google Scholar
• zur Mühlen A, Schwarz C, Mehnert W. (1998). Solid lipid nanoparticles (SLN) for controlled drug delivery – drug release and release mechanism. Eur J Pharmaceut Biopharmaceut 45:149–55
   PubMed Web of Science ®Google Scholar